



RECEIVED
OCT 13 2000

#6

TECH CENTER 1600/2000

Sheet 1 of 5

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. 50069/002002		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		(37 CFR §1.98(b))		Serial No. 09/478,099		
				Applicant Anthony P. Adamis <i>et al.</i>		
				Filing Date January 5, 2000		
				Group 1645 1632		
		IDS Filed		October 4, 2000		
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
AMB	5,707,643	1/13/98	Ogura <i>et al.</i>	424	428	6/7/96
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
AMB	Adamis <i>et al.</i> , "Increased Vascular Endothelial Growth Factor Levels in the Vitreous of Eyes with Proliferative Diabetic Retinopathy," Am. J. Ophthalmol. 118 :445-450 (1994).					
	Adamis <i>et al.</i> , "Inhibition of Vascular Endothelial Growth Factor Prevents Retinal Ischemia-Associated Iris Neovascularization in a Nonhuman Primate," Arch. Ophthalmol. 114 :66-71 (1996).					
	Aiello <i>et al.</i> , "Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders," N. Engl. J. Med. 331 :1480-1487 (1994).					
	Aiello <i>et al.</i> , "Suppression of Retinal Neovascularization <i>In Vivo</i> by Inhibition of Vascular Endothelial Growth Factor (VEGF) Using Soluble VEGF-receptor Chimeric Proteins," Proc. Natl. Acad. Sci. USA 92 :10457-10461 (1995).					
	Amano <i>et al.</i> , "Requirement for Vascular Endothelial Growth Factor in Wound- and Inflammation-Related Corneal Neovascularization," Invest. Ophthalmol. Vis. Sci. 39 :18-22 (1998).					
	Ambati <i>et al.</i> , "Elevated γ -Aminobutyric Acid, Glutamate, and Vascular Endothelial Growth Factor Levels in the Vitreous of Patients with Proliferative Diabetic Retinopathy," Arch. Ophthalmol. 115 :1161-1166 (1997).					
	Arroyo <i>et al.</i> , "In Vivo Photoactivation of Caged-Thrombin," Thromb. Haemost. 78 :791-793 (1997).					
	Asrani <i>et al.</i> , "Feasibility of Laser-Targeted Photoocclusion of the Choriocapillary Layer in Rats," Invest. Ophthalmol. Vis. Sci. 38 :2702-2710 (1997).					
	Barza <i>et al.</i> , "Regional Differences in Ocular Concentration of Gentamicin After Subconjunctival and Retrobulbar Injection in the Rabbit," Am. J. Ophthalmol. 83 :407-413 (1977).					
	Barza <i>et al.</i> , "Transscleral Iontophoresis of Cefazolin, Ticarcillin, and Gentamicin in the Rabbit," Ophthalmology 93 :133-139 (1986).					
↓	Barza <i>et al.</i> , "Intraocular Penetration of Gentamicin After Subconjunctival and Retrobulbar Injection," Amer. J. Ophthalmol. 85 :541-547 (1978).					
AMB	Baum <i>et al.</i> , "Preferred Routes of Antibiotic Administration in Treatment of Bacterial Ulcers of the Cornea," Int. Ophthalmol. Clin. 13 :31-37 (1973).					
EXAMINER			DATE CONSIDERED			
Anne-Marie Baker			8/9/01			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						




RECEIVED

OCT 13 2000

Sheet 2 of 5

TECH CENTER 1600/2900


SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.	50069/002002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Serial No.	09/478,099
				Applicant	Anthony P. Adamis <i>et al.</i>
				Filing Date	January 5, 2000
				Group	4645 1632
(37 CFR §1.98(b))				IDS Filed	October 4, 2000
OTHER DOCUMENTS (INCLUDING AUTHOR; TITLE, DATE; PLACE OF PUBLICATION)					
Amb	Baum <i>et al.</i> , "Treatment of Postcataract Bacterial Endophthalmitis with Periocular and Systemic Antibiotics and Corticosteroids," <i>Trans. Am. Acad. Ophthalmol. Otolaryngo.</i> 81:151-162 (1976).				
	Becker <i>et al.</i> , "In Vivo Significance of ICAM-1-Dependent Leukocyte Adhesion in Early Corneal Angiogenesis," <i>Invest. Ophthalmol. Vis. Sci.</i> 40:612-618 (1999).				
	Bennett <i>et al.</i> , "Photoreceptor Cell Rescue in Retinal Degeneration (<i>rd</i>) Mice by <i>In Vivo</i> Gene Therapy," <i>Nat. Med.</i> 2:649-654 (1996).				
	Bill, "Movement of Albumin and Dextran Through the Sclera," <i>Arch. Ophthalmol.</i> 74:248-252 (1965).				
	Brown <i>et al.</i> , "In Vivo and In Vitro Release of Macromolecules from Polymeric Drug Delivery Systems," <i>J. Pharm. Sci.</i> 72:1181-1185 (1983).				
	Burnette, "Theory of Mass Transfer," In: <i>Controlled Drug Delivery</i> , 2 nd ed 29:95-138 (1987).				
	Cooper <i>et al.</i> , "Transport Across Epithelial Membranes," <i>J. Controlled Release</i> 6:23-35 (1987).				
	DiPolo <i>et al.</i> , "Prolonged Delivery of Brain-derived Neurotrophic Factor by Adenovirus-infected Müller Cells Temporarily Rescues Injured Retinal Ganglion Cells," <i>Proc. Natl. Acad. Sci. USA</i> 95:3978-3983 (1998).				
	Edelhauser <i>et al.</i> , "Permeability of Human Cornea and Sclera to Sulfonamide Carbonic Anhydrase Inhibitors," <i>Arch. Ophthalmol.</i> 106:1110-1115 (1988).				
	Edwards <i>et al.</i> , "Fiber Matrix Model of Sclera and Corneal Stroma for Drug Delivery to the Eye," <i>Am. Inst. Chem. Eng. J.</i> 44:214-225 (1998).				
	Fatt <i>et al.</i> , "Flow of Water in the Sclera," <i>Exptl. Eye Res.</i> 10:243-249 (1970).				
	Husain <i>et al.</i> , "Vascular Endothelial Growth Factor (VEGF) Expression is Correlated with Choroidal Neovascularization in a Monkey Model," <i>Invest. Ophthalmol. Vis. Sci.</i> 38:S501 (1997).				
	Hyndiuk <i>et al.</i> , "Radioactive Depot-Corticosteroid Penetration into Monkey Ocular Tissue. I. Retrobulbar and Systemic Administration," <i>Arch. Ophthalmol.</i> 80:499-503 (1968).				
	Ishibashi <i>et al.</i> , "Expression of Vascular Endothelial Growth Factor in Experimental Choroidal Neovascularization," <i>Arch. Clin. Exp. Ophthalmol.</i> 235:159-167 (1997).				
Amb	Kimura <i>et al.</i> , "A New Vitreal Drug Delivery System Using an Implantable Biodegradable Polymeric Device," <i>Invest. Ophthalmol. Vis. Sci.</i> 35:2815-2819 (1994).				
EXAMINER Anne-Marie Baker			DATE CONSIDERED 8/9/01		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.					



SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.	50069/002002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Serial No.	09/478,099
				Applicant	Anthony P. Adamis <i>et al.</i>
				Filing Date	January 5, 2000
				Group	4615 1632
				IDS Filed	October 4, 2000
(37 CFR §1.98(b))					
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)					
AMB		Kliffen <i>et al.</i> , "Increased Expression of Angiogenic Growth Factors in Age-related Maculopathy," Br. J. Ophthalmol. 81 :154-162 (1997).			
		Lam <i>et al.</i> , "Transscleral Iontophoresis of Dexamethasone," Arch. Ophthalmol. 107 :1368-1371 (1989).			
		Lam <i>et al.</i> , "A Histopathologic Study of Retinal Lesions Inflicted by Transscleral Iontophoresis," Graefes. Arch. Clin. Exp. Ophthalmol. 229 :389-394 (1991).			
		Lang, "Ocular Drug Delivery Conventional Ocular Formulations," Adv. Drug Delivery Rev. 16 :39-43 (1995).			
		Langer <i>et al.</i> , "Polymers for the Sustained Release of Proteins and Other Macromolecules," Nature 263 :797-800 (1976).			
		Lim <i>et al.</i> , "Intraocular Tissue Plasminogen Activator Concentrations after Subconjunctival Delivery," Ophthalmology 100 :373-376 (1993).			
		Lincoff <i>et al.</i> , "Choroidal Concentration of Interferon After Retrobulbar Injection," Invest. Ophthalmol. Vis. Sci. 37 :2768-2771 (1996).			
		Litwack <i>et al.</i> , "Penetration of Gentamicin. Administered Intramuscularly and Subconjunctivally Into Aqueous Humor," Arch. Ophthalmol. 82 :687-693 (1969).			
		Lopez <i>et al.</i> , "Transdifferentiated Retinal Pigment Epithelial Cells Are Immunoreactive for Vascular Endothelial Growth Factor in Surgically Excised Age-Related Macular Degeneration-Related Choroidal Neovascular Membranes," Invest. Ophthalmol. Vis. Sci. 37 :855-868 (1996).			
		Lu <i>et al.</i> , "VEGF Increases Retinal Vascular ICAM-1 Expression In Vivo," Invest. Ophthalmol. Vis. Sci. 40 :1808-1812 (1999).			
		Marmor <i>et al.</i> , "Kinetics of Macromolecules Injected into the Subretinal Space," Exp. Eye Res. 40 :687-696 (1985).			
		Maurice <i>et al.</i> , "Diffusion Across the Sclera," Exp. Eye Res. 25 :577-582 (1977).			
		Melder <i>et al.</i> , "During Angiogenesis, Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor Regulate Natural Killer Cell Adhesion to Tumor Endothelium," Nat. Med. 2 :992-997 (1996).			
✓		Miller <i>et al.</i> , "Vascular Endothelial Growth Factor/Vascular Permeability Factor Is Temporally and Spatially Correlated with Ocular Angiogenesis in a Primate Model," Am. J. Pathol. 145 :574-584 (1994).			
AMB		Misono <i>et al.</i> , "A Study of the Ability of Tissue Plasminogen Activator to Diffuse into the Subretinal Space After Intravitreal Injection in Rabbits," Invest. Ophthalmol. Vis. Sci. 40 :S712 (1999).			
EXAMINER		Anne-Marie Baker		DATE CONSIDERED 8/9/01	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.					



SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE		Attorney Docket No.	50069/002002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	09/478,099
		Applicant	Anthony P. Adamis <i>et al.</i>
		Filing Date	January 5, 2000
		Group	4615 1632
(37 CFR §1.98(b))	IDS Filed	October 4, 2000	
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)			
AMB	Moritera <i>et al.</i> , "Biodegradable Microspheres Containing Adriamycin in the Treatment of Proliferative Vitreoretinopathy," Invest. Ophthalmol. Vis. Sci. 33:3125-3130 (1992).		
	Moritera <i>et al.</i> , "Microspheres of Biodegradable Polymers as a Drug-Delivery System in the Vitreous," Invest. Ophthalmol. Vis. Sci. 32:1785-1790 (1991).		
	Nilsson, "The Uveoscleral Outflow Routes," Eye 11:149-154 (1997).		
	Okamoto <i>et al.</i> , "Transgenic Mice with Increased Expression of Vascular Endothelial Growth Factor in the Retina: A New Model of Intraretinal and Subretinal Neovascularization," Am. J. Pathol. 151:281-291 (1997).		
	Olsen <i>et al.</i> , "Human Sclera: Thickness and Surface Area," Am. J. Ophthalmol. 125:237-241 (1998).		
	Olsen <i>et al.</i> , "Human Scleral Permeability: Effects of Age, Cryotherapy, Transscleral Diode Laser, and Surgical Thinning," Invest. Ophthalmol. Vis. Sci. 36:1893-1903 (1995).		
	Peyman <i>et al.</i> , "Peroxidase diffusion in the Normal and Laser-coagulated Primate Retina," Invest. Ophthalmol. 11:35-45 (1972).		
	Peyman <i>et al.</i> , "Intravitreal Liposome-encapsulated Drugs: A Preliminary Human Report," Int. Ophthalmol. 12:175-182 (1988).		
	Rubsamen, "Prevention of Experimental PVR with Intravitreal Sustained Release of 5-Fluorouracil," Invest. Ophthalmol. Vis. Sci. 33:728 (1992).		
	Ryan, "Subretinal Neovascularization: Natural History of an Experimental Model," Arch. Ophthalmol. 100:1804-1809 (1982).		
	Sakamoto <i>et al.</i> , "Effect of Intravitreal Administration of Indomethacin on Experimental Subretinal Neovascularization in the Subhuman Primate," Arch. Ophthalmol. 113:222-226 (1995).		
	Sanborn <i>et al.</i> , "Sustained-Release Ganciclovir Therapy for Treatment of Cytomegalovirus Retinitis: Use of an Intravitreal Device," Arch. Ophthalmol. 110:188-195 (1992).		
V	Smith <i>et al.</i> , "Intravitreal Sustained-Release Ganciclovir," Arch. Ophthalmol. 110:255-258 (1992).		
AMB	Tolentino <i>et al.</i> , "Vascular Endothelial Growth Factor Is Sufficient to Produce Iris Neovascularization and Neovascular Glaucoma in a Nonhuman Primate," Arch. Ophthalmol. 114:964-970 (1996).		
EXAMINER <i>Anne-Marie Baker</i>		DATE CONSIDERED 8/9/01	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			



Sheet 5 of 5

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.	50069/002002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR §1.98(b))				Serial No.	09/478,099
				Applicant	Anthony P. Adamis <i>et al.</i>
				Filing Date	January 5, 2000
				Group	4615 1632
				IDS Filed	October 4, 2000
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)					
AmB	Tremblay <i>et al.</i> , "Reduced Toxicity of Liposome-Associated Amphotericin B Injected Intravitreally in Rabbits," Invest. Ophthalmol. Vis. Sci. 26:711-718 (1985).				
AmB	Vorwerk <i>et al.</i> , "Chronic Low-Dose Glutamate Is Toxic to Retinal Ganglion Cells. Toxicity Blocked by Memantine," Invest. Ophthalmol. Vis. Sci. 37:1618-1624 (1996).				
AmB	Weijtens <i>et al.</i> , "Peribulbar Corticosteroid Injection: Vitreal and Serum Concentrations After Dexamethasone Disodium Phosphate Injection," Am. J. Ophthalmol. 123:358-363 (1997).				
EXAMINER	Anne-Marie Baker			DATE CONSIDERED	8/9/01
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.					